Turn recording back on
A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004.
Eagye KJ, Nicolau DP, Lockhart SR, Quinn JP, Doern GV, Gallagher G, Abramson MA.
Ann Clin Microbiol Antimicrob. 2007 Oct 1;6:11.
PMID: 17908321 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP.
Clin Ther. 2007 May;29(5):889-99.
PMID: 17697907 [PubMed - indexed for MEDLINE]
Related Articles
Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.
DeRyke CA, Kuti JL, Nicolau DP.
Pharmacotherapy. 2007 Mar;27(3):333-42.
PMID: 17316145 [PubMed - indexed for MEDLINE]
Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS, Frei CR.
J Antimicrob Chemother. 2005 Nov;56(5):893-8. Epub 2005 Sep 14.
PMID: 16162664 [PubMed - indexed for MEDLINE]
Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling.
Eagye KJ, Kuti JL, Nicolau DP.
Surg Infect (Larchmt). 2007 Apr;8(2):215-26.
PMID: 17437367 [PubMed - indexed for MEDLINE]
Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT, Kuti JL, Nicolau DP; OPTAMA Program.
Surg Infect (Larchmt). 2005 Winter;6(4):419-26.
PMID: 16433606 [PubMed - indexed for MEDLINE]
Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.
Maglio D, Kuti JL, Nicolau DP.
Clin Ther. 2005 Jul;27(7):1032-42.
PMID: 16154482 [PubMed - indexed for MEDLINE]
Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Kotapati S, Kuti JL, Nicolau DP.
Surg Infect (Larchmt). 2005 Fall;6(3):297-304.
PMID: 16201939 [PubMed - indexed for MEDLINE]
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Sun HK, Kuti JL, Nicolau DP.
Crit Care Med. 2005 Oct;33(10):2222-7.
PMID: 16215374 [PubMed - indexed for MEDLINE]
Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP.
Int J Antimicrob Agents. 2006 Nov;28(5):433-8.
PMID: 17046212 [PubMed - indexed for MEDLINE]
[Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China]
Wang H, Chen MJ, On Behalf Of China Nosocomial Pathogens Resistance Surveillance Study Group.
Zhonghua Yi Xue Za Zhi. 2003 Mar 10;83(5):385-90. Chinese.
PMID: 12820914 [PubMed - indexed for MEDLINE]
Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
Ellis JM, Kuti JL, Nicolau DP.
Clin Ther. 2005 Nov;27(11):1820-30.
PMID: 16368453 [PubMed - indexed for MEDLINE]
[Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China]
Chen MJ, Wang H; China Nosocomial Pathogens Resistance Surveillance Study Group.
Zhonghua Yi Xue Za Zhi. 2003 Mar 10;83(5):375-81. Chinese.
PMID: 12820912 [PubMed - indexed for MEDLINE]
Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis.
Frei CR, Hampton SL, Burgess DS.
Clin Ther. 2006 Jul;28(7):1035-40.
PMID: 16990081 [PubMed - indexed for MEDLINE]
Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes.
Jones RN, Pfaller MA, Marshall SA, Hollis RJ, Wilke WW.
Diagn Microbiol Infect Dis. 1997 Nov;29(3):187-92.
PMID: 9401811 [PubMed - indexed for MEDLINE]
The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.
Masterton RG, Kuti JL, Turner PJ, Nicolau DP.
J Antimicrob Chemother. 2005 Jan;55(1):71-7. Epub 2004 Dec 1. Erratum in: J Antimicrob Chemother. 2005 Nov;56(5):990.
PMID: 15574471 [PubMed - indexed for MEDLINE]
Continuous infusion beta-lactams for intensive care unit pulmonary infections.
Frei CR, Burgess DS.
Clin Microbiol Infect. 2005 May;11(5):418-21.
PMID: 15819874 [PubMed - indexed for MEDLINE]
Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
Hsueh PR, Chen WH, Luh KT.
Int J Antimicrob Agents. 2005 Dec;26(6):463-72. Epub 2005 Nov 8.
PMID: 16280243 [PubMed - indexed for MEDLINE]
[Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)]
Zarakolu P, Hasçelik G, Unal S.
Mikrobiyol Bul. 2006 Jul;40(3):147-54. Turkish.
PMID: 17001842 [PubMed - indexed for MEDLINE]
Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.
J Antimicrob Chemother. 2006 Nov;58(5):987-93. Epub 2006 Aug 30.
PMID: 16943209 [PubMed - indexed for MEDLINE]